As Europe prepared to receive its first shipments of the Johnson & Johnson coronavirus vaccine, the European Medicines Agency opened an investigation into four serious cases of blood clotting — one of them fatal — reported among recipients of the single-dose shot. The inquiry arrives at a moment of compounding uncertainty: the AstraZeneca vaccine, which shares the same viral vector technology, had already been linked to rare but grave clotting events, and a Dublin woman had been hospitalised with a brain clot after receiving it. Regulators find themselves navigating the ancient tension between
EMA investigates rare blood clots linked to Johnson & Johnson Covid vaccine
One fatal case reported; one Dublin woman hospitalized with brain clot after AstraZeneca vaccination.
No clear causal relationship has been established, yet.
Mark
Why did the EMA wait until the vaccine was about to arrive in Europe to investigate?
Mimi
They didn't wait—the cases were reported in the US first, where the vaccine was already in use. The investigation began as soon as the reports came in. But you're right that the timing felt tight: they were still trying to figure out what they were looking at just as Europe was preparing to roll it out.
Mark
Is this the same problem as the AstraZeneca clots, or something different?
Mimi
Same technology, same basic mechanism—both use a viral vector. That's what made it alarming. You had two different vaccines, built the same way, both showing rare clotting events. It raised the question of whether the problem was specific to one shot or inherent to how these vaccines work.
Mark
The company said no clear causal link had been established. Does that mean it's probably fine?
Mimi
It means they couldn't prove the vaccine caused the clots. But "not proven" isn't the same as "didn't happen." Four people had clots. One died. The regulators needed to figure out whether that was coincidence or signal, and they couldn't do it overnight.
Mark
What about the woman in Dublin?
Mimi
She got the AstraZeneca shot and developed a brain clot. She was treated and recovered. But she was real—not a number in a report. That's what made the regulatory caution feel necessary to people watching from home.
Mark
So what were the authorities supposed to do?
Mimi
That's what the Irish committee was meeting to decide. Do you pause the rollout? Do you restrict it to certain age groups? Do you warn people and let them choose? There was no perfect answer, only the least bad one.
Le Pouls
- One person has died and others have been hospitalised with rare, dangerous blood clots following Johnson & Johnson vaccination, triggering an urgent EMA review just as the vaccine prepares to enter European arms.
- The fact that both J&J and AstraZeneca use the same viral vector platform has raised the unsettling possibility that these clotting events may not be isolated incidents but a pattern tied to the technology itself.
- In Ireland, the crisis is no longer theoretical — a woman in her early forties was treated at Dublin's Mater Hospital for a brain clot after her AstraZeneca jab, putting a human face on what regulators had been tracking as rare statistics.
- Ireland's National Immunisation Advisory Committee convened to decide whether new clinical guidelines were needed, while the EMA simultaneously investigated a separate potential complication — capillary leak syndrome — linked to AstraZeneca.
- Both J&J and regulators insist no causal link has been confirmed, but the accumulation of investigations is reshaping public trust and forcing governments to decide how to proceed with rollouts already underway.
As Europe prepared to receive its first shipments of the Johnson & Johnson coronavirus vaccine, the European Medicines Agency opened an investigation into four serious cases of blood clotting — one of them fatal — reported among recipients of the single-dose shot. The inquiry arrives at a moment of compounding uncertainty: the AstraZeneca vaccine, which shares the same viral vector technology, had already been linked to rare but grave clotting events, and a Dublin woman had been hospitalised with a brain clot after receiving it. Regulators find themselves navigating the ancient tension between the urgency of a public health crisis and the obligation to understand, fully, what they are asking people to accept.
The European Medicines Agency opened an investigation this week into four cases of serious blood clots, accompanied by dangerously low platelet counts, among recipients of the Johnson & Johnson coronavirus vaccine. One of those cases proved fatal. Three arose during the US rollout; a fourth emerged during clinical trials. The agency declined to confirm a causal link, but the timing was difficult to ignore — the first European shipments of the single-dose vaccine were due to arrive the following week.
Johnson & Johnson, which manufactures the shot through its Janssen division, said it was working with medical and regulatory authorities to review the data. The company acknowledged that its own safety monitoring had flagged a small number of extremely rare events but maintained that no clear connection to the vaccine had been established.
The investigation deepened an already unsettling week for vaccine regulators. The EMA had just ruled that brain clots occurring alongside low platelet counts and bleeding should be listed as a very rare side effect of the AstraZeneca vaccine. Both shots rely on the same viral vector technology — a method that uses a modified virus to prime the immune system against the coronavirus. That shared mechanism prompted an uncomfortable question about whether these events reflected an isolated coincidence or something more systemic.
In Ireland, the concern had already taken on a personal dimension. A woman in her early forties had been treated successfully at Dublin's Mater Hospital after developing a brain clot following her AstraZeneca vaccination. The National Immunisation Advisory Committee was meeting that day to consider whether updated clinical guidelines were necessary. Separately, the EMA was also reviewing five reports of capillary leak syndrome — a condition in which fluid escapes blood vessels, causing dangerous drops in blood pressure — potentially linked to AstraZeneca. Taken together, the investigations signalled that regulators were moving with both care and urgency, aware that their conclusions would shape how millions of Europeans thought about vaccination in the critical weeks ahead.
The European Medicines Agency opened an investigation this week into four cases of serious blood clots paired with dangerously low platelet counts among people who received the Johnson & Johnson coronavirus vaccine. One of those cases ended in death. Three emerged during the vaccine rollout in the United States; one surfaced during clinical trials. The agency stopped short of declaring a causal link, saying only that the connection remained unclear. But the timing was significant: the first shipments of the single-dose vaccine were scheduled to arrive in Europe the following week, even as regulators grappled with whether the shots posed a hidden risk.
The Johnson & Johnson company responded by stating it was collaborating with medical experts and regulatory authorities to examine the available data. In a statement, the firm acknowledged that its own safety monitoring had detected a small number of extremely rare events following vaccination, but maintained that no clear causal relationship had been established between these incidents and the vaccine itself. The company manufactures the shot through its Janssen division.
The investigation arrived amid a broader reckoning with blood clotting complications across a class of vaccines. Earlier that same week, the EMA had already determined that blood clots in the brain, occurring alongside low platelet counts and bleeding, should be listed as a very rare side effect of the Oxford-AstraZeneca vaccine. The two shots rely on the same underlying technology—a viral vector approach that uses a modified virus to train the immune system to recognize and fight the coronavirus. That shared mechanism raised an uncomfortable question: were these isolated incidents, or symptoms of a systemic problem?
In Ireland, the situation had already moved beyond the abstract. A woman in her early forties, treated at the Mater Hospital in Dublin, had developed a blood clot in her brain after receiving the AstraZeneca vaccine. She was treated successfully, but the case underscored that these were not merely statistical anomalies confined to regulatory databases. The National Immunisation Advisory Committee, which shapes vaccine policy for the country, was scheduled to meet that day to determine whether new clinical guidelines were needed in light of the emerging evidence.
The EMA was also examining a separate potential complication: capillary leak syndrome, a condition in which fluid seeps from blood vessels into surrounding tissue, causing blood pressure to drop and swelling to develop. The agency had received reports of five cases potentially linked to the AstraZeneca vaccine and was assessing whether a causal connection existed. The accumulation of these investigations—blood clots, low platelets, capillary leakage—painted a picture of regulators moving carefully but urgently to understand whether the vaccines carried risks that had not been apparent in earlier testing. The answers would shape how millions of Europeans approached vaccination in the weeks ahead.
Citations marquantes
Our close tracking of side effects has revealed a small number of very rare events following vaccination. At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.— Johnson & Johnson statement
Envie de l'histoire complète ?
Lire l'original sur Independent.ie ↗
Health & Medicine